Lactobacillus plantarum LRCC 5273 isolated from Kimchi ameliorates diet-induced hypercholesterolemia in C57BL/6 mice

Abstract

This study was designed to select potent cholesterol-lowering probiotic strains on HepG2 cell and investigate the effect of selected strain, Lactobacillus plantarum LRCC 5273 and LRCC 5279 in hypercholesterolemic mice. In the results, LP5273 group showed significantly reduced total and LDL cholesterol compared to HCD group. In addition to significantly up-regulated hepatic mRNA expression of LXR-α and CYP7A1, intestinal LXR-α and ABCG5 were significantly up-regulated in LP5273 group. With activation of hepatic and intestinal LXR-α and its target genes, fecal cholesterol and bile acid excretion were increased in LP5273 fed mice. These results suggest that LP5273 ameliorates hypercholesterolemia in mice through the activation of hepatic and intestinal LXR-α, resulting in enhancement of fecal cholesterol and bile acids excretion in the small intestine. The results of present study suggest mechanistic evidences for hypocholesterolemic effects of L. plantarum spp., and may contribute to future researches for prevention of hypercholesterolemia and cardiovascular disease.

Lactobacillus plantarum 06CC2 reduces hepatic cholesterol levels and modulates bile acid deconjugation in Balb/c mice fed a high‐cholesterol diet

“…Therefore, the expression of hepatic Cyp7A1 protein reflects the hepatic cholesterol level and the influx of bile acid from the enterohepatic circulation (Chiang, 2015). In contrast, several reports showed that LAB ingestion promotes hepatic Cyp7A1 protein expression together with an increase of the efflux as bile acids (Heo et al., 2018; Hu et al., 2013; Qu et al., 2020) It seems that such cholesterol‐reducing mechanism did not occur in this study.…”

Effects of Lactobacillus on hyperlipidemia in high-fat diet-induced mouse model

“…Although AST did not return to the normal range, the results of the hepatic histological examination revealed that the hepatic fatty degeneration improved, which is consistent with the results reported by Oh and Kim [15,16]. Studies have shown that Lactobacillus can improve hypercholesterolemia in mice by activating Lxr-α in the liver and intestine, thereby enhancing the excretion of fecal cholesterol and bile acid in the small intestine [17]. As a probiotic, in addition to reducing blood lipid, it also has antioxidant and anti-inflammatory effects, which can improve the pathology in chronic low-grade inflammation related to obesity or metabolic syndrome [18,19].…”

Evaluation of Bile Salt Hydrolases, Cholesterol-Lowering Capabilities, and Probiotic Potential of Enterococcus faecium Isolated From Rhizosphere

“…De-conjugation of the bile salts by bacterial bile salt hydrolase (BSH) has been reported as an important mechanism that is physiologically associated with the hypo-cholesterolemic effect of probiotics (Begley et al, 2006; Ha et al, 2006; Park et al, 2007). The WHO has recommended that along with capability for colonization of gastrointestinal (GI) epithelia and resistance to harsh GI conditions, BSH activity should be considered as one of the main criteria for selection of probiotics (FAO/WHO, 2002).…”